ProBioGen Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: “Pathway Modulator“
|| Print ||
|Thursday, 14 June 2012 10:00 (UTC + 2)|
Berlin, Germany, June 14, 2012 / B3C newswire / - ProBioGen announced the implementation of its new “Pathway Modulator Technology“, a permanent modification of animal cell lines for substantially improved protein yields. The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.
The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes’ concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.
The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.
The Pathway Modulator Technology can be freely combined with other parts of ProBioGen’s Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies’ Full Pharmaceutical CHO Expression and Media Platform.
ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.
ProBioGen was founded 1994 and is located in Berlin, Germany.
Dr Gabriele Schneider
Vice President Business Development
Phone: +49 (0)30 924 006-0